SEC Info - Evnin Anthony B - ‘4’ for 1/19/23 re: Aveo Pharmaceuticals, Inc.

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

EVNIN ANTHONY B

(Last)

(First)

(Middle)

C/O AVEO PHARMACEUTICALS, INC.

30 WINTER STREET

(Street)

BOSTON

02108

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
AVEO PHARMACEUTICALS, INC. [ AVEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
1/19/23

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	1/19/23		D		41,841	D	$15 ⁽¹⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$25.9	1/19/23		D			1,250	⁽²⁾	5/29/23	Common Stock	1,250	⁽²⁾	0	D
Stock Option (Right to Buy)	$15.7	1/19/23		D			1,250	⁽²⁾	6/19/24	Common Stock	1,250	⁽²⁾	0	D
Stock Option (Right to Buy)	$16.1	1/19/23		D			2,515	⁽²⁾	4/2/25	Common Stock	2,515	⁽²⁾	0	D
Stock Option (Right to Buy)	$20	1/19/23		D			2,000	⁽²⁾	5/28/25	Common Stock	2,000	⁽²⁾	0	D
Stock Option (Right to Buy)	$9.2	1/19/23		D			6,402	⁽²⁾	5/26/26	Common Stock	6,402	⁽²⁾	0	D
Stock Option (Right to Buy)	$7	1/19/23		D			7,785	⁽²⁾	6/21/27	Common Stock	7,785	⁽²⁾	0	D
Stock Option (Right to Buy)	$22.7	1/19/23		D			4,000	⁽²⁾	6/17/28	Common Stock	4,000	⁽²⁾	0	D
Stock Option (Right to Buy)	$7.6	1/19/23		D			4,000	⁽²⁾	6/11/29	Common Stock	4,000	⁽²⁾	0	D
Stock Option (Right to Buy)	$7.52	1/19/23		D			4,000	⁽²⁾	6/9/30	Common Stock	4,000	⁽²⁾	0	D
Stock Option (Right to Buy)	$7.27	1/19/23		D			12,500	⁽²⁾	6/8/31	Common Stock	12,500	⁽²⁾	0	D
Stock Option (Right to Buy)	$4.27	1/19/23		D			22,500	⁽²⁾	6/6/32	Common Stock	22,500	⁽²⁾	0	D

Explanation of Responses:

(1) Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration.

(2) This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.

Remarks:

On January 19, 2022, pursuant to the Agreement and Plan of Merger (as it may be amended from time to time, referred to as the "Merger Agreement"), by and among LG Chem, Ltd. ("Parent"), Acacia acquisition Sub, Inc. ("Merger Sub") and AVEO Pharmaceuticals, Inc. (the "Company"), dated as of October 18, 2022, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of the Company's common stock automatically converted into the right to receive $15.00 per share in cash (the "Merger Consideration").

	/s/ Danielle V. Holland, attorney in fact	1/19/23
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

____________ Transaction Code:
D	Disposition to the Issuer of Issuer equity securities pursuant to Rule 16b-3(e).

Evnin Anthony B – ‘4’ for 1/19/23 re: Aveo Pharmaceuticals, Inc.

On: Thursday, 1/19/23, at 5:16pm ET · For: 1/19/23 · As: Director · Accession #: 899243-23-2193 · File #: 1-34655

Previous ‘4’: ‘4’ on / for 6/16/22 · Latest ‘4’: This Filing

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34

Filing Table of Contents

This ‘4’ Document is an XML Data File that may be rendered in various formats:

Evnin Anthony B – ‘4’ for 1/19/23 re: Aveo Pharmaceuticals, Inc.

On: Thursday, 1/19/23, at 5:16pm ET · For: 1/19/23 · As: Director · Accession #: 899243-23-2193 · File #: 1-34655

Previous ‘4’: ‘4’ on / for 6/16/22 · Latest ‘4’: This Filing

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34Filing Table of Contents

This ‘4’ Document is an XML Data File that may be rendered in various formats:

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34

Filing Table of Contents